Insider Buying: Claritev (NYSE:CTEV) CEO Acquires $75,036.00 in Stock

Claritev (NYSE:CTEVGet Free Report) CEO Travis Dalton bought 1,950 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was acquired at an average cost of $38.48 per share, for a total transaction of $75,036.00. Following the purchase, the chief executive officer owned 52,322 shares in the company, valued at approximately $2,013,350.56. This trade represents a 3.87% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Travis Dalton also recently made the following trade(s):

  • On Thursday, August 27th, Travis Dalton purchased 4,500 shares of Claritev stock. The shares were acquired at an average cost of $38.81 per share, with a total value of $174,645.00.

Claritev Price Performance

NYSE:CTEV opened at $39.98 on Thursday. The business’s 50-day moving average is $31.81 and its two-hundred day moving average is $25.14. Claritev has a 12 month low of $11.50 and a 12 month high of $74.07. The firm has a market capitalization of $677.66 million, a PE ratio of -2.35 and a beta of 0.88.

Claritev (NYSE:CTEVGet Free Report) last posted its earnings results on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.10) by $5.51. The company had revenue of $257.48 million during the quarter. Equities analysts anticipate that Claritev will post -15.13 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Zacks Research raised shares of Claritev from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Citigroup reiterated a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Claritev in a research note on Monday, August 10th. Barclays reaffirmed an “overweight” rating and set a $40.00 target price (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $73.00 price target on shares of Claritev in a report on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.83.

Check Out Our Latest Analysis on Claritev

Hedge Funds Weigh In On Claritev

A number of large investors have recently bought and sold shares of the business. Public Investment Fund acquired a new stake in shares of Claritev during the 2nd quarter worth approximately $43,703,438. Arini Captial Management Ltd acquired a new position in Claritev during the 4th quarter valued at approximately $64,291,000. Beach Point Capital Management LP grew its stake in Claritev by 77.4% during the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock worth $32,276,000 after buying an additional 329,424 shares during the last quarter. State of Wyoming bought a new position in Claritev during the 4th quarter worth $25,000. Finally, California State Teachers Retirement System increased its position in Claritev by 798.0% in the second quarter. California State Teachers Retirement System now owns 4,400 shares of the company’s stock worth $150,000 after buying an additional 3,910 shares during the period. Institutional investors own 87.15% of the company’s stock.

About Claritev

(Get Free Report)

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.

Featured Stories

Insider Buying and Selling by Quarter for Claritev (NYSE:CTEV)

Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.